应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02269 药明生物
未开盘 07-14 16:08:53
38.200
+0.880
+2.36%
最高
38.620
最低
36.020
成交量
3,222万
今开
36.340
昨收
37.320
日振幅
6.97%
总市值
1,583亿
流通市值
1,583亿
总股本
41.44亿
成交额
12.16亿
换手率
0.78%
流通股本
41.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
医药外包概念股普涨 凯莱英(06821)升逾4% 机构指CXO反弹有望获业绩支撑
金吾财讯 · 07-14 10:51
医药外包概念股普涨 凯莱英(06821)升逾4% 机构指CXO反弹有望获业绩支撑
异动解读｜药明生物盘中下跌3.27%，报36.78港元
行情直击 · 07-14 10:03
异动解读｜药明生物盘中下跌3.27%，报36.78港元
【券商聚焦】中信证券：新基药目录有望加速创新药基层落地
金吾财讯 · 07-14 08:57
【券商聚焦】中信证券：新基药目录有望加速创新药基层落地
【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩
金吾财讯 · 07-13 08:53
【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩
异动解读｜药明生物盘中上涨3.45%，MFG8原料药设施获FDA批准持续提振
行情直击 · 07-10
异动解读｜药明生物盘中上涨3.45%，MFG8原料药设施获FDA批准持续提振
药明生物MFG8原料药设施获FDA Pli批准，助推潜在重磅自身免疫疗法商业化供应
美股速递 · 07-09
药明生物MFG8原料药设施获FDA Pli批准，助推潜在重磅自身免疫疗法商业化供应
港股异动 | 药明生物(02269.HK)早盘涨超6% MFG8原液生产厂通过美国FDA上市批准前检查
智通财经 · 07-09
港股异动 | 药明生物(02269.HK)早盘涨超6% MFG8原液生产厂通过美国FDA上市批准前检查
异动解读｜药明生物盘中上涨3.03%，板块反弹叠加持续高频回购提振信心
行情直击 · 07-09
异动解读｜药明生物盘中上涨3.03%，板块反弹叠加持续高频回购提振信心
异动解读｜药明生物盘中下跌3.05%，生命科学板块连续走弱拖累股价
行情直击 · 07-08
异动解读｜药明生物盘中下跌3.05%，生命科学板块连续走弱拖累股价
创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情
金吾财讯 · 07-08
创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情
药明生物7月7日回购271.65万股，耗资约9,982.33万港元
公告速递 · 07-07
药明生物7月7日回购271.65万股，耗资约9,982.33万港元
药明生物(02269)7月7日斥资约9982.33万港元回购271.65万股
智通财经 · 07-07
药明生物(02269)7月7日斥资约9982.33万港元回购271.65万股
异动解读｜药明生物盘中下跌3.02%，报36.66港元
行情直击 · 07-07
异动解读｜药明生物盘中下跌3.02%，报36.66港元
药明生物6月股份变动月报表：已发行股份增至4,143,356,617股
公告速递 · 07-06
药明生物6月股份变动月报表：已发行股份增至4,143,356,617股
异动解读｜药明生物盘中上涨3.09%，持续高频回购叠加板块共振走强
行情直击 · 07-06
异动解读｜药明生物盘中上涨3.09%，持续高频回购叠加板块共振走强
瑞银：升药明生物(02269.HK)目标价至51.1港元 维持“买入”评级
智通财经 · 07-03
瑞银：升药明生物(02269.HK)目标价至51.1港元 维持“买入”评级
异动解读｜药明生物盘中上涨3.4%，持续高频回购叠加巴西GMP认证提振信心
行情直击 · 07-03
异动解读｜药明生物盘中上涨3.4%，持续高频回购叠加巴西GMP认证提振信心
【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间
金吾财讯 · 07-03
【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间
异动解读｜药明生物盘中上涨3.47%，持续高频回购叠加获巴西GMP认证提振信心
行情直击 · 07-02
异动解读｜药明生物盘中上涨3.47%，持续高频回购叠加获巴西GMP认证提振信心
药明生物(02269.HK)6月30日斥资9982.5万港元回购289万股
智通财经 · 06-30
药明生物(02269.HK)6月30日斥资9982.5万港元回购289万股
加载更多
公司概况
公司名称：
药明生物
所属市场：
SEHK
上市日期：
--
主营业务：
药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。
发行价格：
--
{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":38.2,"timestamp":1784016533005,"preClose":37.32,"halted":0,"volume":32220782,"delay":0,"changeRate":0.0235798499464095,"floatShares":4144000000,"shares":4144000000,"eps":1.343363746094699,"marketStatus":"未开盘","change":0.88,"latestTime":"07-14 16:08:53","open":36.34,"high":38.62,"low":36.02,"amount":1215615977,"amplitude":0.069668,"askPrice":38.2,"askSize":9000,"bidPrice":38.18,"bidSize":150000,"shortable":3,"etf":0,"ttmEps":1.343363746094699,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784079000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":37.32,"openAndCloseTimeList":[[1783992600000,1784001600000],[1784005200000,1784016000000]],"volumeRatio":0.8783763776258156,"optionData":{"bulkOrders":[{"symbol":"WXB.HK","call":false,"expireDate":1784217600000,"strike":"37.00","timestamp":1783999442917,"price":0.72,"volume":333,"amount":119880,"type":"*"},{"symbol":"WXB.HK","call":true,"expireDate":1787846400000,"strike":"38.00","timestamp":1784009958785,"price":3.08,"volume":220,"amount":338800,"type":"*"}]},"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.5287,"impliedVolPercentile":0.5714},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2651386126","title":"医药外包概念股普涨 凯莱英(06821)升逾4% 机构指CXO反弹有望获业绩支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2651386126","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651386126?lang=zh_cn&edition=full","pubTime":"2026-07-14 10:51","pubTimestamp":1783997504,"startTime":"0","endTime":"0","summary":"2026年Q2Orforglipron等外企重磅品种获批上市，继续支撑药明康德订单增长。药明康德主动回购也彰显对未来信心，截止2026年6月25日，已回购金额超过10亿元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。自6月8日至7月10日，CRO指数已反弹21.72%。展望下半年，创新药融资增长将继续支持CXO景气度延续。目前CRO龙头企业药明康德2027年预测PE为17.58X，凯莱英为33.19X。随着中期业绩临近，2季度订单趋势逐步明确，CXO反弹有望获得业绩支撑。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985793","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0708995583.HKD","BK0239","BK1515","LU0516422366.SGD","LU0051755006.USD","002821","LU1688375341.USD","CXO","BK1576","06821","LU0039217434.USD","LU0417516738.SGD","LU1720050803.USD","09939","LU0856984785.SGD","LU0823426480.USD","LU0516423174.USD","IE00B0JY6N72.USD","06127","LU2242644610.SGD","LU1794554557.SGD","BK1521","LU0979878070.USD","BK0132","LU0516423091.SGD","LU1046422090.SGD","SG9999002463.SGD","LU0348825331.USD","LU0456827905.SGD","LU2045819591.USD","LU0043850808.USD","BK1574","LU0348735423.USD","LU0516422952.EUR","BK1583","KURE","BK1191","159938","LU0181495838.USD","03347","03759","LU1242518857.USD","LU3063872942.SGD","02269","LU2125910500.SGD","LU0326950275.SGD","LU0327786744.USD","LU0456846285.SGD","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122478252","title":"异动解读｜药明生物盘中下跌3.27%，报36.78港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122478252","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122478252?lang=zh_cn&edition=full","pubTime":"2026-07-14 10:03","pubTimestamp":1783994589,"startTime":"0","endTime":"0","summary":"7月14日，药明生物盘中下跌3.27%，报36.78港元/股，成交额2.37亿港元。药明生物所在的生命科学工具和服务行业中，板块整体表现偏弱，个股中，晶泰控股跌6.61%，金斯瑞生物科技跌2.93%，英矽智能跌2.14%，康龙化成跌0.45%，药明康德涨0.66%。药明生物是全球领先的生物药合同研发和生产组织（CDMO）企业，为全球制药公司提供从药物发现到商业化生产的端到端解决方案及服务，业务覆盖生物药及抗体偶联药物等多个领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","06030","09688","LU1226288253.USD","LU2039709279.SGD","159992","09995","01801","HK0000165453.HKD","KURE","LU0979878070.USD","LU1152091168.USD","BK1500","09926","LU0043850808.USD","LU0572944931.SGD","LU0588546209.SGD","02142","LU1961090484.USD","06160","KCE","BK1161","02616","IBBQ","LU0823426480.USD","LU2328871848.SGD","LU2488822045.USD","BK1610","LU0314109678.HKD","LU1328277881.USD","LU0359201612.USD","06185","LU0327786744.USD","IE00BPRC5H50.USD","01877","IE0008368742.USD","LU1997244956.HKD","LU2476274720.SGD","LU0417516902.SGD","02269","06978","LU0051755006.USD","01177","LU0405327494.USD","LU1242518931.SGD","LU1960683339.HKD","SG9999002463.SGD","01093","MEDX","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1813983027.USD","MEDX","BK1161","BD","02616","IE0008369823.USD","LU2242644610.SGD","IE0008368742.USD","09926","LU0359202008.SGD","159992","LU0348825331.USD","IE00B0JY6N72.USD","01877","LU1960683339.HKD","LU1969619763.USD","LU1688375341.USD","KCE","IBBQ","06185","LU0516422366.SGD","LU2097828631.EUR","BK1515","02142","LU1961090484.USD","LU1993786604.SGD","LU2488822045.USD","LU2097828474.EUR","IE00B5MMRT66.SGD","601066","09995","LU0359201612.USD","LU0348735423.USD","02269","LU0348784397.USD","06160","KURE","LU0456846285.SGD","01801","LU1226288170.HKD","LU0501845795.SGD","BK1588","01177","06978","09688","LU0051755006.USD","LU0455707207.USD","LU0067412154.USD","LU1807302812.USD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159355840","title":"异动解读｜药明生物盘中上涨3.45%，MFG8原料药设施获FDA批准持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1159355840","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159355840?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:50","pubTimestamp":1783648249,"startTime":"0","endTime":"0","summary":"7月10日，药明生物盘中上涨3.45%，报38.34港元/股，成交额1.4亿港元。消息面上，公司旗下MFG8原料药生产设施成功获得美国FDA上市批准前检查批准，为一种潜在重磅自身免疫疗法实现商业化供应迈出关键一步。该认证验证了设施符合国际高标准生产质量体系，为后续大规模稳定药品生产铺平道路，相关疗法上市进程有望加速。瑞银此前上调公司目标价至51.1港元并维持买入评级，当前股价仍有较大折让空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121745953","title":"药明生物MFG8原料药设施获FDA Pli批准，助推潜在重磅自身免疫疗法商业化供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1121745953","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121745953?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:32","pubTimestamp":1783582335,"startTime":"0","endTime":"0","summary":"药明生物旗下MFG8原料药生产设施成功获得美国食品药品监督管理局的Pli批准，此举标志着公司为一种潜在的重磅自身免疫疗法实现商业化供应迈出了关键一步。该认证的取得，不仅验证了设施符合国际高标准的生产质量体系，也为后续大规模、稳定的药品生产铺平了道路。随着监管门槛的跨越，相关疗法的上市进程有望加速，满足未来巨大的市场需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","LU1242518931.SGD","LU1720050803.USD","LU0588546209.SGD","LU0348735423.USD","LU1794554557.SGD","BK1141","LU0359201612.USD","BK1589","LU0327786744.USD","LU0516423091.SGD","LU0320764599.SGD","SG9999002562.SGD","LU0823426308.USD","LU0140636845.USD","IE00B0JY6N72.USD","LU0417516902.SGD","LU0051755006.USD","LU0417516738.SGD","LU0823426480.USD","02269","LU0039217434.USD","LU0819121731.USD","LU0307460666.USD","LU0456846285.SGD","LU0348825331.USD","LU3063872942.SGD","SG9999002463.SGD","KURE","LU0516422366.SGD","LU2039709279.SGD","LU0516422952.EUR","LU0456827905.SGD","LU1688375341.USD","LU0516422440.USD","LU1880383366.USD","LU0181495838.USD","BK1576","BK1610","LU0326950275.SGD","LU0052750758.USD","LU0856984785.SGD","LU0572944931.SGD","LU0979878070.USD","LU0708995583.HKD","LU0359202008.SGD","LU0516423174.USD","LU0043850808.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910638","title":"港股异动 | 药明生物(02269.HK)早盘涨超6% MFG8原液生产厂通过美国FDA上市批准前检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910638","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650910638?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:13","pubTimestamp":1783563221,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","LU0359202008.SGD","LU0456846285.SGD","SG9999002562.SGD","BK1576","02269","LU0052750758.USD","LU0516422366.SGD","LU0823426480.USD","LU1794554557.SGD","LU0708995583.HKD","LU2039709279.SGD","LU0359201612.USD","LU0516423091.SGD","LU0856984785.SGD","LU0572944931.SGD","LU0326950275.SGD","KURE","LU0819121731.USD","SG9999002463.SGD","LU0417516738.SGD","LU0516422952.EUR","BK1521","LU0181495838.USD","LU0417516902.SGD","LU0588546209.SGD","LU0456827905.SGD","LU0979878070.USD","LU0516423174.USD","LU0307460666.USD","IE00B0JY6N72.USD","LU1242518857.USD","LU1242518931.SGD","LU1688375341.USD","LU0516422440.USD","LU0320764599.SGD","LU0051755006.USD","LU0140636845.USD","LU0348735423.USD","LU1720050803.USD","LU0327786744.USD","LU0039217434.USD","BK1589","LU0823426308.USD","LU0043850808.USD","LU3063872942.SGD","LU0348825331.USD","BK1610","LU1880383366.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180230232","title":"异动解读｜药明生物盘中上涨3.03%，板块反弹叠加持续高频回购提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1180230232","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180230232?lang=zh_cn&edition=full","pubTime":"2026-07-09 09:53","pubTimestamp":1783561998,"startTime":"0","endTime":"0","summary":"7月9日，药明生物盘中上涨3.03%，报37.2港元/股，成交额2.54亿港元。消息面上，此前连续两日走弱的生命科学工具和服务板块集体反弹，英矽智能涨7.46%、药明合联涨3.52%、晶泰控股涨2.34%、药明康德涨2.12%，板块共振效应显著。公司维持高频回购节奏，7月7日再度斥资约9982万港元回购271.65万股，年内累计回购金额达12.72亿港元。此外，瑞银此前上调公司目标价至51.1港元并维持买入评级，当前股价较目标价仍有约27%的折让空间。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181293986","title":"异动解读｜药明生物盘中下跌3.05%，生命科学板块连续走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1181293986","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181293986?lang=zh_cn&edition=full","pubTime":"2026-07-08 14:56","pubTimestamp":1783493792,"startTime":"0","endTime":"0","summary":"7月8日，药明生物盘中下跌3.05%，报35.66港元/股，成交额9.42亿港元。消息面上，生命科学工具和服务板块连续第二日普遍走弱，药明康德跌3.33%，药明合联跌3.88%，金斯瑞生物科技跌1.33%，晶泰控股跌1.41%，板块共振效应显著。此前瑞银上调公司目标价至51.1港元并维持买入评级，当前股价较目标价仍有较大折让。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","SG9999002463.SGD","LU0456846285.SGD","CZA","KURE","IBBQ","LU2242644610.SGD","159992","00460","02359","02186","REVS","LU0320764599.SGD","LU0140636845.USD","01672","BK1583","BK1191","BK1600","LU1880383366.USD","SG9999014674.SGD","LU3063872942.SGD","09926","01477","BK1141","01530","06990","LU0516422440.USD","02268","LU0348784397.USD","IE00B0JY6N72.USD","LU0819121731.USD","LU0979878070.USD","LU0326950275.SGD","LU0516423091.SGD","06855","LU0588546209.SGD","01952","BK1521","LU0196878994.USD","LU2476274308.USD","02269","LU0417516571.SGD","06978","BK1515","MEDX","06955","LU0572944931.SGD","LU0052750758.USD","LU1046422090.SGD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121511179","title":"药明生物7月7日回购271.65万股，耗资约9,982.33万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121511179","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121511179?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:55","pubTimestamp":1783432540,"startTime":"0","endTime":"0","summary":"根据公告，公司于2026年7月2日至7月7日期间，因行使2016年1月5日采纳的首次公开发售前购股权计划，共发行普通股206,000股，发行价介乎每股港币1.86至2.19元。受此影响，公司已发行股本由2026年6月30日的4,143,356,617股增至4,143,562,617股。此外，药明生物于2026年7月7日于香港联交所回购普通股2,716,500股，占前一交易日已发行股本约0.06556%，最高回购价为每股港币36.88元，最低回购价为每股港币36.56元，涉及总金额约9,982.33万港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物7月7日回购271.65万股，耗资约9,982.33万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649336019","title":"药明生物(02269)7月7日斥资约9982.33万港元回购271.65万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649336019","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649336019?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:52","pubTimestamp":1783432359,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明生物(02269)发布公告，于2026年7月7日该公司斥资约9982.33万港元回购271.65万股，回购价格为每股36.56至36.88港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348735423.USD","LU1720050803.USD","SG9999002463.SGD","LU0181495838.USD","LU0327786744.USD","SG9999002562.SGD","LU0823426480.USD","LU0856984785.SGD","LU1242518857.USD","LU3063872942.SGD","LU0819121731.USD","LU1688375341.USD","LU0456846285.SGD","BK1141","BK1589","LU0588546209.SGD","LU0043850808.USD","LU0051755006.USD","LU0307460666.USD","LU0359201612.USD","LU0979878070.USD","LU0326950275.SGD","LU0516422440.USD","LU0708995583.HKD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0516422952.EUR","LU0039217434.USD","LU2039709279.SGD","LU0320764599.SGD","LU0348825331.USD","LU0516423091.SGD","BK1521","LU0516423174.USD","LU1880383366.USD","LU0417516902.SGD","BK1610","LU1242518931.SGD","LU0456827905.SGD","LU0140636845.USD","LU0823426308.USD","LU0359202008.SGD","LU0417516738.SGD","KURE","LU1794554557.SGD","LU0052750758.USD","BK1576","LU0572944931.SGD","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164093918","title":"异动解读｜药明生物盘中下跌3.02%，报36.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164093918","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164093918?lang=zh_cn&edition=full","pubTime":"2026-07-07 13:59","pubTimestamp":1783403967,"startTime":"0","endTime":"0","summary":"7月7日，药明生物盘中下跌3.02%，报36.66港元/股，成交额5.57亿港元。药明生物所在的生命科学工具和服务行业中，个股普遍走弱，药明康德跌3.41%，英矽智能跌4.02%，晶泰控股跌4.64%，药明合联跌3.62%，康龙化成涨0.54%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139410800","title":"药明生物6月股份变动月报表：已发行股份增至4,143,356,617股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139410800","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139410800?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:41","pubTimestamp":1783330897,"startTime":"0","endTime":"0","summary":"药明生物技术有限公司于2026年7月6日披露截至2026年6月30日的股份变动月报表。公告显示，公司法定注册股本维持在6,000,000,000股普通股不变，面值为每股USD 0.000008333333，总注册股本折合USD 50,000，较上个月无变动。根据公告，药明生物本月新增已发行股份2,446,181股，主要来源于若干首次公开发售前购股权计划的行使，共带来USD 569,217.16的认股资金。截至报告期末，公司已发行股份由上月的4,140,910,436股增至4,143,356,617股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172876476","title":"异动解读｜药明生物盘中上涨3.09%，持续高频回购叠加板块共振走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1172876476","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172876476?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:12","pubTimestamp":1783303962,"startTime":"0","endTime":"0","summary":"7月6日，药明生物盘中上涨3.09%，报38.72港元/股，成交额3.52亿港元。消息面上，公司维持高频回购节奏，自5月26日以来累计回购逾3710.8万股，总代价约11.72亿港元，彰显管理层对公司内在价值的信心。此外，公司近日宣布无锡生产基地三家工厂以\"零发现项\"通过巴西ANVISA GMP认证，进一步验证其全球商业化生产能力。板块方面，生命科学工具和服务行业个股普遍走强，金斯瑞生物科技涨6.1%、药明合联涨6.0%、晶泰控股涨4.18%，板块共振效应显著。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648365531","title":"瑞银：升药明生物(02269.HK)目标价至51.1港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648365531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648365531?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:36","pubTimestamp":1783056983,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348735423.USD","LU1720050803.USD","SG9999002463.SGD","LU0181495838.USD","LU0327786744.USD","SG9999002562.SGD","LU0823426480.USD","LU0856984785.SGD","LU1242518857.USD","LU3063872942.SGD","LU0819121731.USD","LU1688375341.USD","LU0456846285.SGD","BK1141","BK1589","LU0588546209.SGD","LU0043850808.USD","LU0051755006.USD","LU0307460666.USD","LU0359201612.USD","LU0979878070.USD","LU0326950275.SGD","LU0516422440.USD","LU0708995583.HKD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0516422952.EUR","LU0039217434.USD","LU2039709279.SGD","LU0320764599.SGD","LU0348825331.USD","LU0516423091.SGD","BK1521","LU0516423174.USD","LU1880383366.USD","LU0417516902.SGD","BK1610","LU1242518931.SGD","LU0456827905.SGD","LU0140636845.USD","LU0823426308.USD","LU0359202008.SGD","LU0417516738.SGD","LU1794554557.SGD","LU0052750758.USD","BK1576","LU0572944931.SGD","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190087325","title":"异动解读｜药明生物盘中上涨3.4%，持续高频回购叠加巴西GMP认证提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1190087325","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190087325?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:27","pubTimestamp":1783056441,"startTime":"0","endTime":"0","summary":"7月3日，药明生物盘中上涨3.4%，报37.08港元/股，成交额8.24亿港元。消息面上，公司维持高频回购节奏，自5月26日以来累计回购逾3710.8万股，总代价约11.72亿港元，彰显管理层对公司价值的信心。此外，公司近日宣布无锡生产基地三家工厂以\"零发现项\"通过巴西ANVISA GMP认证，进一步验证全球商业化生产能力。板块方面，生命科学工具和服务行业个股走强，药明合联涨5.02%、金斯瑞生物科技涨2.59%、晶泰控股涨3.48%，板块共振效应显著。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","LU0516422366.SGD","09926","BK1589","01093","LU0348766576.USD","LU0417516738.SGD","02142","09995","LU0417516902.SGD","LU0502904849.HKD","02616","IE00B5MMRT66.SGD","LU2476274308.USD","HK0000165453.HKD","LU1961090484.USD","06160","LU0856984785.SGD","LU0501845795.SGD","LU2097828714.EUR","01177","601066","LU2488822045.USD","SG9999004220.SGD","09688","LU0456846285.SGD","06978","LU1242518931.SGD","IE0008369823.USD","01801","LU2097828631.EUR","06185","02269","159992","01477","01877","LU0067412154.USD","LU0072913022.USD","LU0315179316.USD","LU1226287875.USD","LU2039709279.SGD","LU2476274720.SGD","LU1688375341.USD","LU2778985437.USD","LU3063872942.SGD","LU0043850808.USD","IE00B031HY20.USD","LU1969619763.USD","LU2097828805.USD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114554418","title":"异动解读｜药明生物盘中上涨3.47%，持续高频回购叠加获巴西GMP认证提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1114554418","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114554418?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:10","pubTimestamp":1782958206,"startTime":"0","endTime":"0","summary":"7月2日，药明生物盘中上涨3.47%，报35.92港元/股，成交额5.09亿港元。消息面上，公司近期维持高频回购节奏，6月30日斥资约9982.5万港元回购289万股，自5月26日以来累计回购逾3710.8万股，总代价约11.72亿港元，彰显管理层对公司价值的信心。此外，公司近日宣布其无锡生产基地三家工厂以\"零发现项\"通过巴西ANVISA GMP认证，进一步验证全球商业化生产能力。板块方面，生命科学工具和服务行业个股走强，药明合联涨3.68%、金斯瑞生物科技涨4.33%，板块共振效应显著。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647552508","title":"药明生物(02269.HK)6月30日斥资9982.5万港元回购289万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647552508","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647552508?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:24","pubTimestamp":1782829442,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0572944931.SGD","LU0043850808.USD","LU0327786744.USD","LU0181495838.USD","BK1141","LU2039709279.SGD","BK1589","LU0979878070.USD","LU1242518857.USD","LU0039217434.USD","LU0359201612.USD","LU1242518931.SGD","LU0359202008.SGD","LU0417516902.SGD","BK1576","LU0456846285.SGD","LU0856984785.SGD","LU0516423091.SGD","LU0516423174.USD","LU1720050803.USD","IE00B0JY6N72.USD","BK1610","LU0348735423.USD","LU0456827905.SGD","LU0051755006.USD","LU0516422366.SGD","LU0708995583.HKD","LU1688375341.USD","LU1880383366.USD","LU0516422440.USD","BK1521","LU0819121731.USD","LU0516422952.EUR","LU0320764599.SGD","LU0307460666.USD","LU0052750758.USD","SG9999002463.SGD","LU0326950275.SGD","LU0823426480.USD","LU3063872942.SGD","02269","LU1794554557.SGD","LU0348825331.USD","LU0823426308.USD","LU0588546209.SGD","LU0140636845.USD","SG9999002562.SGD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":0.0386},{"period":"1month","weight":0.2291},{"period":"3month","weight":0.0324},{"period":"6month","weight":-0.0455},{"period":"1year","weight":0.428},{"period":"ytd","weight":0.215}],"compareEarnings":[{"period":"1week","weight":0.0359},{"period":"1month","weight":-0.0153},{"period":"3month","weight":-0.0619},{"period":"6month","weight":-0.0959},{"period":"1year","weight":0.0057},{"period":"ytd","weight":-0.0503}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.002485},{"month":6,"riseRate":0.666667,"avgChangeRate":0.061606},{"month":7,"riseRate":0.7,"avgChangeRate":0.083727},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}